Study of the Impact of an Intervention Performed by a Clinical Pharmacist on Patients at Risk of Pneumococcal Infection at the End of Hospitalization

NCT04734925 | Completed

• 1 other identifier: LOCAL/2019/DF-01
• Study Type: observational
• Target: 167
• Locations: 1 country
• Sites: 1

Brief Summary

In France, Streptococcus pneumoniae is the leading agent involved in community-acquired bacterial pneumopathies and bacterial meningitis. The frequency of these infections is increasing in at-risk subjects. Paradoxically, pneumococcal vaccination coverage in this type of patient is limited at the national level, even though the French High Council for Public Health (HCSP) has been extending the 13-valent conjugate and 23-valent non-conjugate double vaccination in this target population since March 2017. These patients generally benefit from regular medical follow-up involving several health professionals in hospital or outpatient clinics. In spite of this, one of the factors identified as a hindrance to pneumococcal vaccination is the absence of a proposal from the doctor. We would like to assess compliance with the recommendations for pneumococcal vaccination according to the High Council of Public Health (HCSP) in at-risk patients leaving hospital. We also wish to measure the potential impact of an intervention by the clinical pharmacist on the application of these recommendations.

Conditions

Vaccination

Keywords

antipneumococcal

Outcome Measures

Primary Outcomes (1)

• vaccine protocols dispensed by dispensing pharmacists.

  number of vaccine protocols

  3 month

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

patients hospitalized in the Vascular Surgery and Pneumology Departments of Nimes University Hospital

You may qualify if:

• Hospitalization in one of the departments participating in the study
• At risk of pneumococcal infection according to HCSP recommendations (1)
• Negative pneumococcal vaccination status
• Adult patient (≥18 years old)

You may not qualify if:

• Under safeguard of justice
• Unable to receive informed information
• Patient having objected to the use of their data.

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes: lead

Study Sites (1)

Chu Nimes

Nîmes, 30029, France

Location

Related Publications (1)

• Chiappin M, Leguelinel-Blache G, Roux-Marson C, Kinowski JM, Dubois F. Impact of a clinical pharmacist's intervention on pneumococcal vaccination in a population of at- risk hospitalized patients: The IP-VAC study. Infect Dis Now. 2023 Oct;53(8):104765. doi: 10.1016/j.idnow.2023.104765. Epub 2023 Jul 25.

  PMID: 37499757 RESULT

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 28, 2021
• First Posted: February 2, 2021
• Study Start: March 1, 2020
• Primary Completion: October 22, 2020
• Study Completion: October 22, 2020
• Last Updated: December 4, 2025

Record last verified: 2025-02

Locations

FR (1)